Psychiatric features in children with genetic syndromes: Toward functional phenotypes

Pediatric Clinics of North America

Volumn 58, Issue 4, 2011, Pages 833-864

  Siegel, Matthew S ^a,b,c   Smith, Wendy E ^d,e  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Spring Harbor Hospital   (United States)

^c MAINE MEDICAL CENTER   (United States)

^d Barbara Bush Children's Hospital   (United States)

^e Maine Medical Partners   (United States)

Author keywords

Behavioral; Children; Genetic; Neuropsychiatric; Phenotype

Indexed keywords

ACETYLCARNITINE; DEXAMPHETAMINE; METHYLPHENIDATE;

ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CHILD DEVELOPMENT; CHILD PSYCHIATRY; CLINICAL FEATURE; DIGEORGE SYNDROME; DOSE RESPONSE; DOWN SYNDROME; FRAGILE X SYNDROME; FUNCTIONAL DISEASE; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC DISORDER; GENETIC SCREENING; HAPPY PUPPET SYNDROME; HUMAN; LESCH NYHAN SYNDROME; LOW DRUG DOSE; MOLECULAR DIAGNOSIS; PATHOGENESIS; PHENOTYPE; PHENYLKETONURIA; PRADER WILLI SYNDROME; PROTEIN RESTRICTION; PSYCHOLOGIC ASSESSMENT; RETT SYNDROME; REVIEW; SMITH MAGENIS SYNDROME; TREATMENT OUTCOME; TURNER SYNDROME; WILLIAMS BEUREN SYNDROME;

EID: 80051686543     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2011.06.010     Document Type: Review

References (202)

1. Reiss A.L. Childhood developmental disorders: an academic and clinical convergence point for psychiatry, neurology, psychology and pediatrics. J Child Psychol Psychiatry 2009, 50(1-2):87-98.
2. Skuse D.H. Behavioural phenotypes: what do they teach us?. Arch Dis Child 2000, 82:222-225.
3. Reiss S., Levitan G.W., Szysko J. Emotional disturbance and mental retardation: diagnostic overshadowing. Am J Ment Defic 1982, 86(6):567-574.
4. Dykens E.M., Rosner B.A. Psychopathology in persons with Williams-Beuren syndrome. Williams-Beuren syndrome: research, evaluation and treatment 2006, 274-293. The Johns Hopkins University press, Baltimore (MD). 1st edition. C.A. Morris, H.M. Lenhoff, P.P. Wang (Eds.).
5. Feinstein C., Singh S. Social phenotypes in neurogenetic syndromes. Child Adolesc Psychiatr Clin N Am 2007, 16(3):631-648.
6. Besser L.M., Shin M., Kucik J.E., et al. Prevalence of Down syndrome among children and adolescents in metropolitan Atlanta. Birth Defects Res A Clin Mol Teratol 2007, 79:765-774.
7. Bittles A.H., Glasson E.J. Clinical, social, and ethical implications of changing life expectancy in Down syndrome. Dev Med Child Neurol 2004, (46):282-286.
8. Driscoll D.A., Gross S.J. On behalf of the professional practice guidelines committee. Screening for fetal aneuploidy and neural tube defects. Genet Med 2009, 11(11):818-821.
9. Torfs C.P., Christianson R.E. Anomalies in Down syndrome individuals in a large population based registry. Am J Med Genet 1998, 77:431-438.
10. Goldberg-Stern H., Strawsburg R.H., Patterson B., et al. Seizure frequency and characteristics in children with Down syndrome. Brain Dev 2001, 23:375-378.
11. Prasher V.P. Down syndrome and thyroid disorders: a review. Downs Syndr Res Pract 1999, 6:25-42.
12. Hill I., Dirks M., Liptak G., et al. Guidelines for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol 2004, 40(1):1-19.
13. American Academy of Pediatrics Committee on Genetics Health supervision for children with Down syndrome. Pediatrics 2001, 107:442-449.
14. Miller J.F. Individual differences in vocabulary acquisition in children with Down syndrome. Prog Clin Biol Res 1995, 393:93-103.
15. Myers B.A., Pueschel S.M. Psychiatric disorders in persons with Down syndrome. J Nerv Ment Dis 1991, 179(10):609-613.
16. Pueschel S.M., Myers B.A. Environmental and temperament assessments of children with Down's syndrome. J Intellect Disabil Res 1994, 38(pt2):195-202.
17. Pueschel S.M., Gallagher P.L., Zartler A.S., et al. Cognitive and learning processes in children with Down syndrome. Res Dev Disabil 1987, 8(1):21-37.
18. State M.W., King B.H., Dykens E. Mental retardation: a review of the past 10 years. Part II. J Am Acad Child Adolesc Psychiatry 1997, 36(12):1664-1669.
19. Capone G., Goyal P., Ares W., et al. Neurobehavioral disorders in children, adolescents, and young adults with Down syndrome. Am J Med Genet 2006, 142C(3):158-172.
20. Dykens E.M., Shah B., Sagun J., et al. Maladaptive behavior in children and adolescents with Down's syndrome. J Intellect Disabil Res 2002, 46:484-492.
21. Evans D.W., Gray F.L. Compulsive-like behavior in individuals with Down syndrome: its relation to mental age level, adaptive, and maladaptive behavior. Child Dev 2000, 71(2):288-300.
22. Cooper S.A., Collacott R.A. Clinical features and diagnostic criteria of depression in Down's syndrome. Br J Psychiatry 1994, 165(3):399-403.
23. Pary R.J., Loschen E.L., Tomkowiak S.B. Mood disorders and down syndrome. Semin Clin Neuropsychiatry 1996, 1(2):148-153.
24. Ghaziuddin M. Autism in Down's syndrome: a family history study. J Intellect Disabil Res 2000, 44(Pt 5):562-566.
25. Heller J.H., Spiridigliozzi G.A., Crissman B.G., et al. Safety and efficacy of rivastigimine in adolescents with Down syndrome: a preliminary 20-week, open-label study. J Child Adolesc Psychopharmacol 2006, 16(6):755-765.
26. Strom C.M., Crossley B., Redman J.B., et al. Molecular testing for Fragile X syndrome: lessons learned from 119,232 tests performed in a clinical laboratory. Genet Med 2007, 9:46-51.
27. Sherman S., Pletcher B.A., Driscoll D.A. Fragile X syndrome: diagnostic and carrier testing. Genet Med 2005, 7:584-587.
28. American Academy of Pediatrics Committee on Genetics Health supervision for children with Fragile X syndrome. Pediatrics 1996, 98:297-300.
29. Jacquemont S., Hagerman R.J., Leehey M.A., et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. J Am Med Assoc 2004, 291:460-469.
30. Tarleton J.C., Saul R.A. Molecular genetic advances in fragile X syndrome. J Pediatr 1993, 122:169-185.
31. Lachiewicz A.M., Dawson D.V., Spiridiglioaai G.A. Physical characteristics of young boys with Fragile X syndrome: reasons for difficulties in making a diagnosis in young males. Am J Med Genet 2000, 92:229-236.
32. Hagerman R.J., Hagerman P.J. The fragile X premutation: into the phenotypic fold. Curr Opin Genet Dev 2002, 12:278-283.
33. Grigsby J, Bennett R, Brega A, et al. Fragile X-associated tremor-ataxia syndrome (FXTAS): An X-linked neurodegenerative phenotype. Presented at the American College of Medical Genetics Meeting. Dallas (TX), 2005 [Abstract #280].
34. Dykens E.M., Hodapp R.M., Evnas D.W. Profiles and development of adaptive behavior in children with Down syndrome. Am J Ment Retard 1994, 98(5):580-587.
35. Mazzocco M.M. Advances in research on the Fragile X syndrome. Ment Retard Dev Disabil Res Rev 2000, 6(2):96-106.
36. Skinner M., Hooper S., Hatton D.D., et al. Mapping nonverbal IQ in young boys with Fragile X syndrome. Am J Med Genet Am 2005, 132(1):25-32.
37. Hagerman R.J., Hills J., Scharfenaker S., et al. Fragile X syndrome and selective mutism. Am J Med Genet 1999, 83(4):313-317.
38. Franke P., Leboyer M., Gansicke M., et al. Genotype-phenotype relationship in female carriers of the permutation and full mutation of FMR-1. Psychiatry Res 1998, 80(2):113-127.
39. Cornish K., Kogan C., Turk J., et al. The emerging Fragile X permutation phenotype: evidence from the domain of social cognition. Brain Cogn 2005, 57(1):53-60.
40. Hatton D.D., Bailey D.B., Hargett-Beck M.Q., et al. Behavioral style of young boys with Fragile X syndrome. Dev Med Child Neurol 1999, 41(9):625-632.
41. Miller L.J., Mcintosh D.N., McGrath J., et al. Electrodermal responses to sensory stimuli in individuals with Fragile X syndrome: a preliminary report. Am J Med Genet 1999, 83(4):26-79.
42. Roberts J.E., Boccia M.L., Bailey D.B., et al. Cardiovascular indices of physiological arousal in boys with Fragile X syndrome. Dev Psychobiol 2001, 39(2):107-123.
43. Garrett A.S., Menon V., MacKenzie K. Here's looking at you, kid: neural systems underlying face and gaze processing in Fragile X syndrome. Arch Gen Psychiatry 2004, 61(3):281-288.
44. Hall S.S., Lightbody A.A., Huffman L.C. Physiologic correlates of social avoidance behavior in children and adolescents with Fragile X syndrome. J Am Acad Child Adolesc Psychiatry 2009, 48(3):320-329.
45. Hall S., DeBernardis M., Reiss A. Social escape behaviors in children with Fragile X syndrome. J Autism Dev Disord 2006, 36(7):935-947.
46. Sabaratnam M., Murthy N.V., Wijeratne A., et al. Autistic-like behaviour profile and psychiatric morbidity in Fragile X syndrome: a prospective ten-year follow-up study. Eur Child Adolesc Psychiatry 2003, 12(4):172-177.
47. Hall S.S., Maynes N.P., Reiss A.L. Using percentile schedules to increase eye contact in children with Fragile X syndrome. J Appl Behav Anal 2009, 42(1):171-176.
48. Hagerman R.J., Fulton M.J., Leaman A., et al. A survey of fluoxetine therapy in Fragile X syndrome. Dev Brain Dysfunct 1994, 7:155-164.
49. Hagerman R.J. Lessons from Fragile X regarding neurobiology, autism, and neurodegeneration. J Dev Behav Pediatr 2006, 27(1):63-74.
50. Cohen I.L., Tsiouris J.A., Pfadt A. Effects of long acting propranolol on agonistic and stereotyped behaviors in a man with pervasive developmental disorder and Fragile X syndrome:a double blind, placebo controlled study. J Clin Psychopharmacol 1991, 11(6):398-399.
51. Hagerman R.J., Murphy M.A., Wittenberger M.D. A controlled trial of stimulant medication in children with Fragile X syndrome. Am J Med Genet 1988, 30(1-2):377-392.
52. Hagerman R.J. Influence of stimulants on electrodermal studies in Fragile X syndrome. Microsc Res Tech 2002, 57:168-173.
53. Torrioli M.G., Nernacotola S., Mariotti P., et al. Double-blind, placebo-controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in Fragile X syndrome. Am J Med Genet 1999, 87(4):366-368.
54. Hagerman R.J., Riddle J.E., Roberts L.S., et al. A survey of the efficacy of clonidine in Fragile X syndrome. Dev Brain Dysfunction 1995, 8:336-344.
55. Hilton D.K., Martin C.A., Heffron W.M., et al. Imipramine treatment of ADHD in a Fragile X child. J Am Acad Child Adolesc Psychiatry 1991, 30(5):831-834.
56. Reiss A.L., Hall S.S. Fragile X syndrome: assessment and treatment implications. Child Adolesc Psychiatr Clin N Am 2007, 16(3):668.
57. Laurvick C.L., de Klerk N., Bower C., et al. Rett syndrome in Australia: a review of the epidemiology. J Pediatr 2006, 148:347-352.
58. Ellaway C., Christodoulou J. Rett syndrome: clinical characteristics and recent genetic advances. Disabil Rehabil 2001, 23:98-106.
59. Kammoun F., de Roux N., Boespflug-Tanguy O., et al. Screening of MECP2 coding sequence in patients with phenotypes of decreasing likelihood for Rett syndrome: a cohort of 171 cases. J Med Genet 2004, 41:e85.
60. Li M.R., Pan H., Bao X.H., et al. MECP2 and CDKL5 gene mutation analysis in Chinese patients with Rett syndrome. J Hum Genet 2007, 52:38-47.
61. Weaving L.S., Williamson S.L., Bennetts B., et al. Effects of MECP2 mutation type, location and X-inactivation in modulating Rett syndrome phenotype. Am J Med Genet Am 2003, 118:103-114.
62. Archer H.L., Whatley S.D., Evans J.C., et al. Gross rearrangements of the MECP2 gene are found in both classical and atypical Rett syndrome patients. J Med Genet 2006, 43:451-456.
63. Hagberg B., Hanefeld F., Percy A., et al. An update on clinically applicable diagnostic criteria in Rett syndrome: comments to Rett Syndrome Clinical Criteria Consensus Panel Satellite to European Paediatric Neurology Society Meeting, Baden Baden, Germany, 11 September 2001. Europ J Paediatr Neurol 2002, 6:293-297.
64. Hagberg B., Gilberg C. Rett syndrome, clinical and biological aspects, Rett Variants-Rettoid types, Clinics in Developmental Medicine 1993, vol. 127. MacKeith Cambridge University Press, Cambridge (UK), p. 40-60.
65. Witt-Engerström I. Rett syndrome in Sweden. Acta Paediatr Scand 1990, 369(Suppl):1-60.
66. Cass H., Reilly S., Owen L., et al. Findings from a multidisciplinary clinical case series of females with Rett syndrome. Dev Med Child Neurol 2003, 45(5):325-337.
67. Lavas J., Slotte A., Jochym-Nygren M., et al. Communication and eating proficiency in 125 females with Rett syndrome: the Swedish Rett Center Survey. Disabil Rehabil 2006, 28(20):1267-1279.
68. Lotan M., Ben-Zeev B. Rett syndrome. A review with emphasis on clinical characteristics and intervention. Scientific World Journal 2006, 6(6):1517-1541.
69. Ben-Zeev B. Rett syndrome. Child Adolesc Psychiatr Clin N Am 2007, 16(3):723-724.
70. Monaghan K.G., Wiktor A., Van Dyke D.L. Diagnostic testing for Prader-Willi syndrome and Angelman syndrome: a cost comparison. Genet Med 2002, 4:448-450.
71. Holm V.A., Cassidy S.B., Butler M.G., et al. Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 1993, 91:398-402.
72. Gunay-Aygun M., Schwartz S., Heeger S., et al. The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria. Pediatrics 2001, 108:E92.
73. Eiholzer U., l'Allemand D., van der Sluis I., et al. Body composition abnormalities in children with Prader-Willi syndrome and long-term effects of growth hormone therapy. Horm Res 2000, 53:200-206.
74. Hoybye C. Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment. Growth Horm IGF Res 2004, 14:1-15.
75. Curfs L.M., Fryns J.P. Prader-Willi syndrome: a review with special attention to the cognitive and behavioral profile. Birth Defects Orig Artic Ser 1992, 28(1):99-104.
76. Benarroch F., Hirsch H.J., Gentsil L. Prader-Willi syndrome: medical prevention and behavioral challenges. Child Adolesc Psychiatr Clin N Am 2007, 16(3):695-708.
77. Stein D.J., Keating J., Zar H.J., et al. A survey of the phenomenology and pharmacotherapy of compulsive and impulsive-aggressive symptoms in Prader Willi syndrome. J Neuropsychiatry Clin Neurosci 1994, 6(1):23-29.
78. Dykens E.M., Leckman J.F., Cassidy S.B. Obsessions and compulsions in Prader-Willi syndrome. J Child Psychol Psychiatry 1996, 37:995-1002.
79. Dykens E.M., Cassidy S.B. Correlates of maladaptive behavior in children and adults with Prader-Willi syndrome. Am J Med Genet 1995, 60(6):546-549.
80. Koenig K., Klin A., Schultz R. Deficits in social attribution ability in Prader-Willi syndrome. J Autism Dev Disord 2004, 34(5):573-582.
81. Vogels A., De Hert M., Descheemaeker M.J., et al. Psychotic disorders in Prader-Willi syndrome. Am J Med Genet 2004, 127A(3):238-243.
82. Boer H., Holland A., Whittington J., et al. Psychotic illness in people with Prader Willi syndrome due to chromosome 15 maternal uniparental disomy. Lancet 2002, 359(9301):135-136.
83. Soni S., Whittington J., Holland A.J. The course and outcome of psychiatric illness in people with Prader-Willi syndrome: implications for management and treatment. J Intellect Disabil Res 2007, 51:32-42.
84. Symons F.J., Butler M.G., Sanders M.D., et al. Self-injurious behavior and Prader-Willi syndrome: behavioral forms and body locations. Am J Ment Retard 1999, 104(3):260-269.
85. Whitman B.Y. Tools for psychological and behavioral management. Management of Prader-Willi syndrome 2006, 317-343. Springer, New York. 3rd edition. M.G. Butler (Ed.).
86. Roof E, The use of psychotropic medications in Prader-Willi syndrome. Presented at the 20th Annual PWSA (USA) National Conference. Orlando (FL), July 27, 2005.
87. Dykens E., Shah B. Psychiatric disorders in Prader-Willi syndrome: epidemiology and management. CNS Drugs 2003, 17:167-178.
88. Hellings J.A., Warnock J.K. Self-injurious behavior and serotonin in Prader-Willi syndrome. Psychopharmacol Bull 1994, 30(2):245-250.
89. Shapira N.A., Lessig M.C., Lewis M.H. Effects of topiramate in adults with Prader-Willi syndrome. Am J Ment Retard 2004, 109(4):301-309.
90. Smathers S.A., Wilson J.G., Nigro M.A. Topiramate effectiveness in Prader-Willi syndrome. Pediatr Neurol 2003, 28(2):130-133.
91. Gupta B.K., Fish D.N., Yerevanian B.I. Carbamazepine for intermittent explosive disorder in a Prader-Willi syndrome patient. J Clin Psychiatry 1987, 48(10):423.
92. Jerome L. Prader-Willi and bipolar illness. J Am Acad Child Adolesc Psychiatry 1993, 32(4):876-877.
93. Durst R., Rubin-Jabotinksy K., Raskin S. Risperidone in treating behavioural disturbances of Prader-Willi syndrome. Acta Psychiatr Scand 2000, 102(6):461-465.
94. Wigren M., Hansen S. ADHD symptoms and insistence on sameness in Prader-Willi syndrome. J Intellect Disabil Res 2005, 49(6):449-456.
95. Knoll J.H., Nicholls R.D., Magenis R.E., et al. Angelman and Prader Willi syndromes share a common chromosome 15 deletion but differ in parental origin of the deletion. Am J Med Genet 1989, 32:285-290.
96. ASHG/ACMG Diagnostic testing for Prader-Willi and Angelman syndromes: Report of the ASHG/ACMG test and technology transfer committee. Am J Hum Genet 1996, 58:1085-1088.
97. Clayton-Smith J., Pembrey M.E. Angelman syndrome. J Med Genet 1992, 29:412-415.
98. Steffenburg S., Gillberg C.L., Steffenburg U., et al. Autism in Angelman syndrome: a population-based study. Pediatr Neurol 1996, 14:131-136.
99. Williams C.A., Beaudet A.L., Clayton-Smith J., et al. Angelman syndrome 2005: updated consensus for diagnostic criteria. Am J Med Genet Am 2006, 140:413-418.
100. Horsler K., Oliver C. Environmental influences on the behavioral phenotype of Angelman syndrome. Am J Ment Retard 2006, 111(5):311-321.
101. Artigas-Pallares J., Brun-Gasca C., Gabau-Vila E., et al. Aspectos medicos y conductuales del syndrome Angelman. Rev Neurol (Madrid) 2005, 41:649-656.
102. Barry R.J., Leitner R.P., Clarke A.R. Behavioral aspects of Angelman syndrome: a case control study. Am J Med Genet Am 2005, 132(1):8-12.
103. Pelc K., Cheron G., Boyd S.G., et al. Are there distinctive sleep problems in Angelman syndrome?. Sleep Med 2008, 9(4):434-441.
104. Clarke D., Marston G. Problem behaviours associated with 15q- Angelman syndrome. Am J Ment Retard 2000, 105:25-31.
105. Williams J.C.P., Barrett-Boyes B.G., Lowe J.B. Supravalvar aortic stenosis. Circulation 1961, 24:1311-1318.
106. Buren A.J., Apitz J., Harmjanz D. Supravalvar aortic stenosis in association with mental retardation and a certain facial appearance. Circulation 1962, 27:1235-1240.
107. Garcia R.E., Friedman W.F., Kaback M.M., et al. Idiopathic hypercalcemia and supravalvar aortic stenosis. N Engl J Med 1964, 27:117-120.
108. Ewart A.K., Morris C.A., Atkinson D., et al. Hemizygosity at the elastin locus in a developmental disorder, Williams syndrome. Nat Genet 1993, 5:11-16.
109. Frangiskakis J.M., Ewart A.K., Morris C.A., et al. LIM-kinase 1 hemizygosity implicated in impaired visuospatial constructive cognition. Cell 1996, 86:59-69.
110. Morris C.A., Mervis C.B., Hobart H.H., et al. GTF2I hemizygosity implicated in mental retardation in Williams syndrome: genotype-phenotype analysis of five families with deletions in the Williams syndrome region. Am J Med Genet Am 2003, 123(1):45-59.
111. American Academy of Pediatrics Committee on Genetics Health supervision for children with Wiliams syndrome. Pediatrics 2001, 107:1192-1204.
112. Mervis C.B., Klein-Tasman B.P. Williams syndrome: cognition, personality and adaptive behavior. Ment Retard Dev Disabil Res Rev 2000, 6(2):148-158.
113. Jones W., Bellugi U., Lai Z., et al. Hypersociability in Williams syndrome. J Cogn Neurosci 2000, 12(Suppl 1):30-46.
114. Bellugi U., Adolphs R., Cassidy C. Towards the neural basis for hypersociability in a genetic syndrome. Neuroreport 1999, 22(5):197-207.
115. Frigerio E., Burt D.M., Gagliardi C. Is everybody always my friend? Perception of approachability in Williams syndrome. Neuropsychologia 2006, 44(2):254-259.
116. Gagliardi C., Frigerio E., Burt D.M., et al. Facial expression recognition in Williams syndrome. Neuropsychologia 2003, 41(6):733-738.
117. Gosch A., Pankau R. Personality characteristics and behavior problems in individuals of different ages with Williams syndrome. Dev Med Child Neurol 1997, 39(8):527-533.
118. Plesa-Skwerer D., Tager-Flusberg H. Social cognition in Williams-Seuren syndrome. Williams-Beuren syndrome 2006, 237-253. Johns Hopkins University Press, Baltimore (MD). C.A. Morris, H.M. Lenhoff, P.P. Wang (Eds.).
119. Dykens E.M. Anxiety, fears and phobias in persons with Williams syndrome. Dev Neuropsychol 2003, 23(1-2):291-316.
120. Spence S.H., McCathie H. The stability of fears in children: a two-year prospective study: a research note. J Child Psychol Psychiatry 1993, 34(4):579-585.
121. Leyfer O.T., Woodruff-Borden J., Klein-Tasman B.P., et al. Prevalence of psychiatric disorders in 4 to 16-year-olds with Williams syndrome. Am J Med Genet Br 2006, 141(6):615-622.
122. Power T.J., Blum N.J., Jones S.M., et al. Brief report: response to methylphenidate in two children with Williams syndrome. J Autism Dev Disord 1997, 27(1):79-87.
123. Bawden H.N., MacDonald G.W., Shea S. Treatment of children with Williams syndrome with methylphenidate. J Child Neurol 1997, 12(4):248-252.
124. Arens R., Wright B., Elliott J., et al. Periodic limb movement in sleep in children with Williams syndrome. J Pediatr 1998, 133(5):670-674.
125. Botto L.D., May K., Fernhoff P.M., et al. A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. Pediatrics 2003, 112:101-107.
126. Merscher S., Funke B., Epstein J.A., et al. TBX1 is responsible for cardiovascular defects in velo-cardio-facial/DiGeorge syndrome. Cell 2001, 104:619-629.
127. Lachman H.M., Morrow B., Shprintzen R.J., et al. Association of codon 108/158 catechol-o-methyl transferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genet 1996, 67:468-472.
128. Sirotkin H., Morrow B., DasGupta, et al. Isolation of a new clathrin heavy chain gene with muscle-specific expression from the region commonly deleted in velo-cardio-facial syndrome. Hum Mol Genet 1996, 5:617-624.
129. Sagoo G.S., Butterwort A.S., Sanderson S., et al. Array CGH in patients with learning disability (mental retardation) and congenital anomalies: updated systematic review and meta-analysis of 19 studies and 13,926 subjects. Genet Med 2009, 11(3):139-146.
130. Carlson C., Sirotkin H., Pandita R., et al. Molecular definition of 22q11 deletions in 151 velo-cardio-facial syndrome patients. Am J Hum Genet 1997, 61:620-629.
131. Rauch A., Zink S., Zweier, et al. Systematic assessment of atypical deletions reveals genotype-phenotype correlation in 22q11.2. J Med Genet 2005, 42:871-876.
132. Swillen A., Devriendt K., Vantrappen G., et al. Familial deletions of 22q11.2: the Leuven experience. An J Med Genet 1998, 80:531-532.
133. Kates W.R., Antshel K., Roizen N., et al. Velo-cardio-facial syndrome. Genetics of developmental disabilities 2004, Marcel Dekker, New York, p. 383-418. M.G. Butler, F.J. Meaney (Eds.).
134. Shprintzen R.J., Morrow B., Kucherlapati R. Vascular anomalies may explain many of the features of velo-cardio-facial syndrome. Am J Hum Genet 1997, 61:34A.
135. Matsuoka R., Takao A., Kimura M., et al. Confirmation that the conotruncal anomaly face syndrome is associated with a deletion within 22q11.2. Am J Med Genet 1994, 53:285-289.
136. McDonald-McGinn D.M., Driscoll D.A., Bason L., et al. Autosomal dominant "Opitz" GBBB syndrome due to a 22q11.2 deletion. Am J Med Genet 1995, 59:103-113.
137. Giannotti A., Digilio M.C., Marino B., et al. Cayler cardiofacial syndrome and del 22q11: part of the CATCH22 phenotype. Am J Med Genet 1994, 53:303-304.
138. Wang P.P., Woodlin M.F., Kreps-Falk R., et al. Research on behavioral phenotypes: velocardiofacial syndrome. Dev Med Child Neurol 2000, 42(6):422-427.
139. Shprintzen R.J., Goldberg R.B., Young D., et al. The velo-cardio-facial syndrome: a clinical and genetic analysis. Pediatrics 1981, 67(2):167-172.
140. Gothelf D. Velocardiofacial syndrome. Child Adolesc Psychiatr Clin N Am 2007, 16(3):677-694.
141. Feinstein C., Eliez S., Blasey C., et al. Psychiatric disorders and behavioral problems in children with velocardiofacial syndrome: usefulness as phenotypic indicators of schizophrenia risk. Biol Psychol 2002, 51(4):312-318.
142. Gothelf D., Feinstein C., Thompson T., et al. Risk factors for the emergence of psychotic disorders in adolescents with 22q11.2 deletion syndrome. Am J Psychiatry 2007, 164(4):663-669.
143. Gothelf D., Presburger G., Zohar A.H., et al. Obsessive-compulsive disorder in patients with velocardiofacial (22q11 deletion) syndrome. Am J Med Genet 2004, 126B(1):99-105.
144. Woodlin M., Wang P.P., Aleman D., et al. Neuropsychological profile of children and adolescents with the 22q11.2 microdeletion. Genet Med 2001, 3(1):34-39.
145. Vorstman J.A., Morcus M.E., Duijff S.N., et al. The 22q11.2 deletion in children: high rate of autistic disorders and early onset of psychotic symptoms. J Am Acad Child Adolesc Psychiatry 2006, 45(9):1104-1113.
146. Gothelf D., Frisch A., Munitz H., et al. Clinical characteristics of schizophrenia associated with velo-cardio-facial syndrome. Schizophr Res 1999, 35(2):105-112.
147. Pulver A.E., Nestadt G., Goldberg R. Psychotic illness in patients diagnosed with velo-cardio-facial syndrome and their relatives. J Nerv Ment Dis 1994, 182(8):476-478.
148. Sporn A., Addington A., Reiss A.L., et al. 22q11 deletion syndrome in childhood onset schizophrenia: an update. Mol Psychiatry 2004, 9(3):225-226.
149. Gothelf D., Michaelovsky E., Frisch A., et al. Association of the low-activity COMT 158Met allele with ADHD and OCD in subjects with velocardiofacial syndrome. Int J Neuropsychopharmacol 2007, 10(3):301-308.
150. Gothelf D., Gruber R., Presburger G., et al. Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. J Clin Psychiatry 2003, 64(10):1163-1169.
151. Graf W.D., As Unis, Yates C.M., et al. Catecholamines in patients with 22q11.2 deletion syndrome and the low-activity COMT polymorphism. Neurology 2001, 57(3):410-416.
152. Smith A.C.M., McGavran L., Waldstein G. Deletion of the 17 short arm in two patients with facial clefts. Am J Med Genet 1982, 34(Suppl):A410.
153. Smith A.C.M., McGavran L., Robinson J., et al. Interstitial deletion of (17) (p11.2p11.2) in nine patients. Am J Med Genet 1986, 24:393-414.
154. Stratton R.F., Dobns W.B., Greenberg F., et al. Interstitial deletion of (17) (p11.2p11.2): report of six additional patients with a new chromosome deletion syndrome. Am J Med Genet 1986, 24:421-432.
155. Behjati F., Mullarkey M., Bergbaum A., et al. Chromosome deletion 17p11.2 (Smith-Magenis syndrome) in seven new patients, four of whom had been referred for fragile X investigation. Clin Genet 1997, 51:71-74.
156. Elsea S.H., Purandare S.M., Adell R.A., et al. Definition of the critical interval for Smith-Magenis syndrome. Cytogenet Cell Genet 1977, 79:276-281.
157. Lucas R.E., Vlangos C.N., Das P., et al. Genomic organization of the approximately 1.5 Mb Smith-Magenis syndrome critical interval: transcription map, genomic contig, and candidate gene analysis. Eur J Hum Genet 2001, 9:892-902.
158. Bi W., Yan J., Stankiewicz P., et al. Genes in a refined Smith-Magenis syndrome critical deletion interval on chromosome 17p11.2 and the syntenic region of the mouse. Genome Res 2002, 12:713-728.
159. Vlangos C.N., Yim D.K.C., Elsea S.H. Refinement of the Smith-Magenis syndrome critical region to ∼950kb and assessment of 17p11.2 deletions. Are all deletions created equally?. Mol Genet Metab 2003, 79(2):134-141.
160. Potocki L., Shaw C.J., Stankiewicz P., et al. Variability in clinical phenotype despite common chromosomal deletion in Smith-Magenis syndrome [del(17)(p11.2p11.2)]. Genet Med 2003, 5(6):430-434.
161. Slager R.E., Newton T.L., Vlangos C.N., et al. Mutations in RAI1 associated with Smith-Magenis syndrome. Nat Genet 2003, 33:466-468.
162. Gropman A., Smith A.C.M., Allanson J., et al. Smith Magenis syndrome: aspects of the infant phenotype. Am J Hum Genet 1998, 63(Suppl):A19.
163. Gropman A., Wolters P., Smith A.C.M. Neurodevelopmental assessment and functioning in five young children with Smith-Magenis syndrome. Am J Hum Genet 1999, 65(Suppl):A141.
164. Udwin O., Webber C., Horn I. Abilities and attainment in Smith-Magenis syndrome. Dev Med Child Neurol 2001, 43(12):823-828.
165. Madduri N., Peters S.U., Voigt R.G., et al. Cognitive and adaptive behavior profiles in Smith-Magenis syndrome. J Dev Behav Pediatr 2006, 27(3):188-192.
166. Dykens E.M., Finucane B.M., Gayley C. Brief report: cognitive and behavioral profiles in persons with Smith-Magenis syndrome. J Autism Dev Disord 1997, 27(2):203-211.
167. Smith A.C., Dykens E., Greenberg F. Behavioral phenotype of Smith-Magenis syndrome (del 17p11.2). Am J Med Genet 1998, 81(2):179-185.
168. De Leersnyder H., de Blois M.C., Vekemans M., et al. Beta(1)-adrenergic antagonists improve sleep and behavioural disturbances in a circadian disorder, Smith-Magenis syndrome. J Med Genet 2001, 38(9):586-590.
169. De Leersnyder H. Inverted rhythm of melatonin secretion in Smith-Magenis syndrome: from symptoms to treatment. Trends Endocrinol Metab 2006, 17(7):291-298.
170. Finucane B., Dirrigi K.H., Simon E.W. Characterization of self-injurious behaviors in children and adults with Smith-Magenis syndrome. Am J Ment Retard 2001, 106(1):52-58.
171. Finucane B.M., Konar D., Haas-Givler B. The spasmodic upper-body squeeze: a characteristic behavior in Smith-Magenis syndrome. Dev Med Child Neurol 1994, 36(1):78-83.
172. Taylor L., Oliver C. The behavioural phenotype of Smith-Magenis syndrome: evidence for a gene-environment interaction. J Intellect Disabil Res 2008, 52(10):830-841.
173. Dykens E.M., Smith A.C. Distinctiveness and correlates of maladaptive behavior in children and adolescents with Smith-Magenis syndrome. J Intellect Disabil Res 1998, 42(Pt 6):481-489.
174. Niederhofer H. Efficacy of risperidone treatment in Smith-Magenis syndrome. Psychiatr Danub 2007, 19(3):189-192.
175. Sybert V.P. The adult patient with Turner syndrome. Turner syndrome in a life span perspective: research and clinical aspects 1995, 205-218. Elsivier, New York. K. Albertson-Wikland, M.B. Ranke (Eds.).
176. Gotzsche C.O., Krag-Olsen B., Nielsen J., et al. Prevalence of cardiovascular malformations and association with karyotypes in Turner's syndrome. Arch Dis Child 1994, 71:433-436.
177. Arulanantham K., Kramer M.S., Gryboski J.D. The association of inflammatory bowel disease and X chromosome abnormality. Pediatrics 1980, 66:63-67.
178. Germain E.L., Plotnick L.P. Age-related anti-thyroid antibodies and thyroid abnormalities in Turner syndrome. Acta Paediatr Scand 1986, 75:750-755.
179. Lippe B., Geffner M.E., Dietrich R.B., et al. Renal malformations in patients with Turner syndrome: Imaging in 141 patients. Pediatrics 1988, 82:852-856.
180. American Academy of Pediatrics Committee on Genetics Health supervision for children with Turner syndrome. Pediatrics 1995, 96:1166-1173.
181. Ross J.L., Stefanatos G.A., Kushner H., et al. Persistent cognitive deficits in adult women with Turner syndrome. Neurology 2002, 58(2):218-225.
182. Russell H.F., Wallis D., Mazzocco M.M., et al. Increased Prevalence of ADHD in Turner syndrome with no evidence of imprinting effects. J Pediatr Psychol 2006, 31(9):945-955.
183. Siegel P.T., Clopper R., Stabler B. The psychological consequences of Turner syndrome and review of the National Cooperative Growth Study psychological substudy. Pediatrics 1998, 102(2 Pt 3):488-491.
184. Mazzocco M.M., Baumgardner T., Freund L.S., et al. Social functioning among girls with Fragile X or Turner syndrome and their sisters. J Autism Dev Disord 1998, 28(6):509-517.
185. McCauley E., Kay T., Ito J., et al. The Turner syndrome: cognitive deficits, affective discrimination, and behavior problems. Child Dev 1987, 58(2):464-473.
186. Ross J.L., Stefanatos G., Roeltgen D., et al. Ullrich-Turner syndrome: neurodevelopmental changes from childhood through adolescence. Am J Med Genet 1995, 58(1):74-82.
187. Rae C., Joy P., Harasty J., et al. Enlarged temporal lobes in Turner syndrome: an X-chromosome effect?. Cereb Cortex 2004, 14(2):156-164.
188. Lawrence K., Campbell R., Swettenham J. Interpreting gaze in Turner syndrome: impaired sensitivity to intention and emotion, but preservation of social cueing. Neuropsychologia 2003, 41(8):894-905.
189. Skuse D.H., Morris J.S., Dolan R.J. Functional dissociation of amygdale-modulated arousal and cognitive appraisal in Turner syndrome. Brain 2005, 128(pt 9):2084-2096.
190. Kesler S.R. Turner syndrome. Child Adolesc Psychiatr Clin N Am 2007, 16(3):709-722.
191. Anderson L.T., Ernst M. Self-injury in Lesch-Nyhan disease. J Autism Dev Disord 1994, 24(1):67-81.
192. Harris J.C. Developmental neuropsychiatry 1995, vol II. Oxford University Press, New York, p. 307.
193. Taira T., Kobayashi T., Hori T. Disappearance of self-mutilating behavior in a patient with Lesch-Nyhan syndrome after bilateral chronic stimulation of the globus pallidus interna. J Neurosurg 2003, 98(2):414-416.
194. Lesch M., Nyhan W.L. A familial disorder of uric acid metabolism and central nervous system dysfunction. Am J Med 1964, 36:561-570.
195. Arnold G.L., Kramer B.M., Kirby R.S., et al. Factors affecting cognitive, motor, behavioral and executive functioning in children with phenylketonuria. Acta Paediatr 1998, 87:565-570.
196. Griffiths P., Tarrini M., Robinson P. Executive function and psychosocial adjustment in children with early treated phenylketonuria; correlation with historical and concurrent phenylalanine levels. J Intellect Disabil Res 1997, 41:317-323.
197. Pietz J., Fatkenheur B., Burgard P., et al. Psychiatric disorders in adult patients with early-treated phenylketonuria. Pediatrics 1997, 99:345-350.
198. Realmuto G., Garfinkle B.D., Tuchman M., et al. Psychiatric diagnosis and behavioral characteristics of phenylketonuric children. J Nerv Ment Dis 1986, 174:536-540.
199. Seashore M.R., Freidman E., Novelly R.A., et al. Loss of intellectual function in children with phenylketonuria after relaxation of dietary phenylalanine restriction. Pediatrics 1985, 75:226-232.
200. Williams K. Benefits of normalizing plasma phenylalanine: impact on behavior and health. J Inherit Metab Dis 1998, 21:785-790.
201. Enns G.M. Neurologic damage and neurocognitive dysfunction in urea cycle disorders. Semin Pediatr Neurol 2008, 15(3):132-139.
202. Gropman A.L., Batshaw M.L. Cognitive outcome in urea cycle disorders. Mol Genet Metab 2004, 81:S58-S62.